ArticleCancers2020
SPON2 Is Upregulated through Notch Signaling Pathway and Promotes Tumor Progression in Gastric Cancer.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Identification and functional validation of SPON2 as a novel biomarker for the diagnosis and prognosis in hepatocellular carcinoma.Journal of gastrointestinal oncology · 2026Article
- Upregulation of spondin-2 indicates poorer clinical outcomes and induces radioresistance in gastric cancer.Translational cancer research · 2025Article
- Single-cell sequencing reveals the role ofiMeta · 2025Article
- SPON2 facilitates osteosarcoma development by inducing M2 macrophage polarization through activation of the NF-κB/VEGF signaling axis.Cell death discovery · 2025Article
- Kindlin-1 promotes gastric cancer cell motility through the Wnt/β-catenin signaling pathway.Scientific reports · 2025Article
- Immunodiagnostic profiling of SPON2 and MSMB as biomarkers in prostate cancer for nanomaterial- based detection strategies.Frontiers in immunology · 2025Article
- Knockdown of IGF2BP2 overcomes cisplatin-resistance in lung cancer through downregulating Spon2 gene.Hereditas · 2024Article
- Progress and prospects of biomarker-based targeted therapy and immune checkpoint inhibitors in advanced gastric cancer.Frontiers in oncology · 2024Review
- Epigenetic Regulation of MAP3K8 in EBV-Associated Gastric Carcinoma.International journal of molecular sciences · 2023Article
- Knockdown of SPON2 inhibits the growth of triple-negative breast cancer.Frontiers in oncology · 2023Article
- miRNA-223-3p regulates ECT2 to promote proliferation, invasion, and metastasis of gastric cancer through the Wnt/β-catenin signaling pathway.Journal of cancer research and clinical oncology · 2023Article
- The biological functions and related signaling pathways of SPON2.Frontiers in oncology · 2023Review
- Tumor-derived exosomal HOTAIRM1 regulates SPON2 in CAFs to promote progression of lung adenocarcinoma.Discover oncology · 2022Article
- Analysis of Collagen type X alpha 1 (COL10A1) expression and prognostic significance in gastric cancer based on bioinformatics.Bioengineered · 2021Article
- miR-138-5p inhibits proliferation and invasion in kidney renal clear cell carcinoma by targeting SINA3 and regulation of the Notch signaling pathway.Journal of clinical laboratory analysis · 2021Article
- Article
- The clinical significance of spondin 2 eccentric expression in peripheral blood mononuclear cells in bronchial asthma.Journal of clinical laboratory analysis · 2021Article
- Implications for preeclampsia: hypoxia-induced Notch promotes trophoblast migration.Reproduction (Cambridge, England) · 2021Article
- The Study of Cancer Susceptibility Genes.Cancers · 2021Article
- SLC6A8 is involved in the progression of non-small cell lung cancer through the Notch signaling pathway.Annals of translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Spondin-2 (SPON2) is involved in cancer progression and metastasis of many tumors; however, its role and underlying mechanism in gastric cancer are still obscure. In this study, we investigated the role of SPON2 and related signaling pathway in gastric cancer progression and metastasis. SPON2 expression levels were found to be upregulated in gastric cancer cell lines and patient tissues compared to normal gastric epithelial cells and normal controls. Furthermore, SPON2 silencing was observed to decrease cell proliferation and motility and reduce tumor growth in xenograft mice. Conversely, SPON2 overexpression was found to increase cell proliferation and motility. Subsequently, we focused on regulatory mechanism of SPON2 in gastric cancer. cDNA microarray and in vitro study showed that Notch signaling is significantly correlated to SPON2 expression. Therefore, we confirmed how Notch signaling pathway regulate SPON2 expression using Notch signaling-related transcription factor interaction and reporter gene assay. Additionally, activation of Notch signaling was observed to increase cell proliferation, migration, and invasion through SPON2 expression. Our study demonstrated that Notch signaling-mediated SPON2 upregulation is associated with aggressive progression of gastric cancer. In conclusion, we suggest upregulated SPON2 via Notch signaling as a potential target gene to inhibit gastric cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.